Notícias Teva Pharmaceutical Industries Ltd - TEVA | Ações New York Stock Exchange | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NYSE
Teva Pharmaceutical Industries Ltd (TEVA)
Teva Pharmaceutical Industries Ltd (TEVA) Notícias

Teva Pharmaceutical Industries Ltd (TEVA)

17,73

-0,11

(-0,62%)

Fechado 03 Fevereiro 6:00PM

Atrasado por 15 minutos

17,74

0,01

(0,06%)

Após o horário de negociação: 9:58PM

Atrasado por 15 minutos

Capacite seu portfólio: Discussões em tempo real e ideias de negociação acionáveis.

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States

Form 4 - Statement of changes in beneficial ownership of securities

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Teva Pharmaceutical Indu...

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições